Myeloma UK’s new CEO begins her role

pharmafile | June 28, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Myeloma UK 

Myeloma UK, the only organisation in the UK dealing exclusively with myeloma, will have a new CEO in place from today onwards, as Rosemarie Finley joins the charity from the Epilepsy Society and begins the role today.

Finley brings along with her more than 30 years of management experience in the healthcare sector. She began her care in healthcare as a nurse before working as a Publishing Director for Emap Healthcare and as Head of Children and Young People Services for Community Health Buckinghamshire.

As mentioned, her role immediately prior to joining Myeloma UK was with the Epilepsy Society, where she held the position of Acting CEO and COO.

Commenting on her appointment, Rosemarie Finley said, “It is a privilege to be joining Myeloma UK, an organisation with a distinct reputation for putting patients at the heart of its strategy and for working collaboratively. I am looking forward to bringing my expertise of operating in highly complex healthcare environments to drive the organisation forward. Our aim will continue to be the acceleration of improved care, effective treatments and ultimately a cure for myeloma.”

Judy Dewinter, Chairman of Myeloma UK, said, “I am delighted that Rosemarie is joining us as Chief Executive. She comes to us with a wealth of experience and a track record of strong leadership. Rosemarie combines her strong commitment to patients and the health and research agenda, with a clear understanding of the healthcare system and how to operate effectively within it. This is absolutely central to our work. The whole team looks forward to working with Rosemarie, as Myeloma UK enters a new and exciting phase in its journey.”

Related Content

Eric Low

Open access research partnership to ‘crowdsource’ new myeloma drugs

Myeloma UK and the Structural Genomics Consortium (SGC) have entered into an open-access research partnership …

Latest content